{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977333",
  "id": "02977333",
  "pages": 21,
  "price_sensitive": true,
  "date": "20250806",
  "time": "0829",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml1j2n9zwnr0.pdf",
  "summary": "### **Material Information Summary: ACCENT Trial Topline Data (6 August 2025)**  \n\n#### **Key Clinical Trial Results**  \n- **Progression-Free Survival (PFS):** **7.6 months** (vs. 5.5 months for standard chemotherapy in MPACT study).  \n- **Durability:** Mean **Days on Trial (DOT) of 202 days** (vs. 117 days for chemotherapy).  \n- **Response Rates:**  \n  - **Objective Response Rate (ORR): 31%** (vs. 23% for chemotherapy).  \n  - **Disease Control Rate (DCR): 73%** (vs. 50% for chemotherapy).  \n  - Includes **1 confirmed Complete Response (CR)** and **1 pathological Complete Response (pCR)**.  \n- **Tolerability:** Safety profile similar to chemotherapy alone, with no significant additional adverse events.  \n\n#### **Upcoming Catalysts**  \n- **Further ACCENT trial updates expected in 2H 2025.**  \n- **Mature data (including Overall Survival) expected in Q1 2026.**  \n- **Planned pivotal Phase 2b/3 trial initiation in 2H 2026.**  \n\n#### **Regulatory & Pipeline Developments**  \n- **FDA Fast Track and Orphan Drug Designation granted.**  \n- **US Phase 1b/2a \"AMPLICITY\" trial (narmafotinib + FOLFIRINOX) to begin imminently.**  \n\n#### **Investment Implications**  \n- Positive interim data supports **potential superiority over standard chemotherapy** in pancreatic cancer.  \n- Upcoming milestones (FDA engagement, pivotal trial planning) **key for valuation re-rating.**  \n\n**No material capital structure or financing updates identified.**  \n\n---  \n*Processed under strict ECM-focused filtering. Excluded operational details, disclaimers, and non-material pipeline commentary.*",
  "usage": {
    "prompt_tokens": 5411,
    "completion_tokens": 399,
    "total_tokens": 5810,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T22:47:23.235339"
}